Adjuvant therapy in completely resected non-small-cell lung cancer.
Less than 20% to 25% of patients with non-small-cell lung cancer (NSCLC) present with stage I or II disease and are best treated by surgical resection. Long-term survival in early NSCLC remains poor. The 5-year survival rate of patients who undergo complete surgical resection is only 40% to 50%. The majority of relapses after surgery are distant metastases; the risk of a local recurrence after complete resection is less than 10%. Postoperative treatments, including chemotherapy, radiotherapy, or both modalities together, have been evaluated widely, but unfortunately none of these treatments have demonstrated any significant impact on survival. Data regarding large-scale adjuvant chemotherapy trials that were closed for accrual almost 4 to 5 years ago will be fully available before the end of the year. It is hoped that a specific meta-analysis will be performed on the basis of these data.